Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest Angiogenesis Stories

2012-02-09 10:00:00

WOBURN, Mass., Feb. 9, 2012 /PRNewswire/ -- MBL International Corporation, a leading life science company focused on providing high quality products and solutions for life science research and clinical diagnostics, today announced the launch of AngioPhase(TM), an angiogenesis kit which allows for the analysis of all known phases of the angiogenic process in a convenient and flexible format. Angiogenesis is the multistep process whereby new blood vessels develop from pre-existing...

2012-02-06 06:00:00

ROCKVILLE, Md., Feb. 6, 2012 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today that Wei-Wu He, Ph.D has joined the Board of Directors as Executive Chairman and Tak W. Mak, Ph.D has joined as a member of the Board of Directors. (Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO ) Dr. Wei-Wu He is currently the CEO and Chairman of OriGene Technologies, Inc. He also is the founder...

2012-01-30 08:00:00

SAN DIEGO, Jan. 30, 2012 /PRNewswire/ -- Cardium Therapeutics (NYSE Amex: CXM) today reported on new insights and confirmatory preclinical study results on the Generx (Ad5FGF-4) angiogenic therapy product candidate based on the Company's sponsored research conducted at Emory University. The findings, which provide further support for the apparent safety and effectiveness of Generx as a potential one-time non-surgical approach to the treatment of coronary heart disease, are being...

2012-01-30 06:00:00

MELBOURNE, Australia, Jan. 30, 2012 /PRNewswire/ -- Circadian Technologies Limited (ASX: CIR, OTCQX: CKDXY) announced today the publication of data in the scientific journal, Investigative Ophthalmology & Visual Science (IOVS), showing that VEGF-C expression is markedly up-regulated in corneal graft rejection. Importantly the data also showed that VEGF-C blockade, through administration of Circadian's lead development candidate VGX-100, a human antibody against VEGF-C,...

2012-01-25 12:38:01

Finding could explain limited success of anti-angiogenesis treatments in breast cancer Cancer treatments designed to block the growth of blood vessels were found to increase the number of cancer stem cells in breast tumors in mice, suggesting a possible explanation for why these drugs don't lead to longer survival, according to a new study by researchers at the University of Michigan Comprehensive Cancer Center. The drugs Avastin and Sutent have been looked at as potential breast cancer...

2012-01-18 06:29:54

(Ivanhoe Newswire) — A new study found that a group of little-explored cells in the tumor microenvironment can likely serve as gatekeepers against cancer progression and metastasis. One known way of treating cancer is by targeting angiogenesis, or blood vessel growth. Raghu Kalluri, MD, PhD, Chief of the Division of Matrix Biology at Beth Israel Deaconess Medical Center (BIDMC) and Professor of Medicine at Harvard Medical School (HMS) and colleagues, hypothesized whether targeting a...

2012-01-18 00:07:26

Paradoxical discovery finds that a group of cells known as pericytes help prevent metastasis A new study finds that a group of little-explored cells in the tumor microenvironment likely serve as important gatekeepers against cancer progression and metastasis. Published in the January 17 issue of Cancer Cell, these findings suggest that anti-angiogenic therapies — which shrink cancer by cutting off tumors' blood supply — may inadvertently be making tumors more aggressive and...

2012-01-17 22:38:41

New research explains how cells regulate their bonds during the development of new blood vessels. For the first time, the role of the protein Raf-1 in determining the strength of the bond between cells has been shown. If Raf-1 is not present, the cells cannot stick together and the formation of new blood vessels is inhibited. This discovery may one day lead to new approaches to cancer treatment. Angiogenic sprouting, the process by which new blood vessels grow from existing vessels, is a...

2012-01-10 21:26:40

Researchers at Linköping University are now launching a plan to effectively treat psoriasis. About 300 000 Swedes suffer from the difficult to treat disease, which manifests itself in scaly and often itchy patches on the skin. The reason is that cells divide without restraint as new blood vessels form in the deeper layers of the skin. An important component is the psoriasin protein (S100A7), which are abundant in psoriasis-affected skin but rarely in normal skin. The same...

2012-01-08 16:30:00

MELBOURNE, Australia, Jan. 8, 2012 /PRNewswire/ -- Circadian Technologies Limited (ASX:CIR, OTCQX:CKDXY) announced today that it has commenced the first Phase 1 clinical trial of its fully human monoclonal antibody against VEGF-C, VGX-100, at a leading US-based cancer treatment centre. The Phase 1 study will examine the safety and tolerability of escalating doses of VGX-100 in patients with advanced solid tumours who have no other standard treatment options both as a monotherapy and also...